Trogenix
A biotechnology company developing precision gene therapies for cancer treatment using a proprietary synthetic super-enhancer platform.
Trogenix has raised €80M across 1 funding round from 1 investor, most recently a Series A round in Oct 2025. Based in Edinburgh, UK; active in Healthtech. Data as of 28 Oct 2026.
Edinburgh, UKwww.trogenixbio.com ↗
Total raised
€80M
€80,432,035
Funding rounds
1
Investors
1
distinct backers
Active since
2025-10
latest 2025-10
Funding by year
EUR raised per yearTrogenix — funding by year — interactive chart.
Data table
| Trogenix — funding by year | |
|---|---|
| 2025 | €80M |
Signals
High confidenceRaise-next likelihood61
base rate 44% for Series A
- ▲ In typical raise window
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-10-07 | Series A | €80M | IQ Capital | View deal → |